Quantcast

Latest Targeted therapy Stories

2014-09-29 16:23:53

In the news release, The Gastric Cancer Market is Expected to More Than Triple Over the Next Ten Years, Capturing Nearly $3.8 million by 2023, issued 18-Sep-2014 by Decision

2014-09-29 08:31:17

Additional Study Focuses on the Detection and Quantitative Monitoring of EGFR Mutations in Lung Cancer Patients SAN DIEGO, Sept.

2014-09-22 08:28:11

Presentations include first Phase 2 results evaluating investigational compound Veliparib in patients with non-small cell lung cancer NORTH CHICAGO, Ill., Sept.

2014-09-18 12:27:44

Several Emerging Therapies Will Expand Treatment Armamentarium for Unresectable Locally Advanced or Metastatic Gastric Cancer, According to Findings from Decision Resources Group BURLINGTON,

2014-09-10 12:28:10

The Emergence of Keytruda--the First PD-1 Inhibitor Approved in the U.S.--is a Significant Milestone in Oncology, According to Decision Resources Group BURLINGTON, Mass., Sept.

2014-08-11 12:26:57

Significant Opportunity Exists for New Therapies to Treat GIST, Particularly those for Treating Unresectable and/or Metastatic Disease in Later-Line Settings BURLINGTON, Mass., Aug.

2014-08-04 08:27:33

- Results from Phase I program in glioblastoma multiforme presented at ASCO earlier this year NORTH CHICAGO, Ill., Aug.

2014-07-15 23:14:44

Targeted therapy for pancreatic cancer is based on personalized medicine approach Somerville, Massachusetts (PRWEB) July 15, 2014 ANDARIX Pharmaceuticals,


Word of the Day
deuteragonist
  • A person in a secondary role, specifically the second most important character (after the protagonist).
The word 'deuteragonist' comes from a Greek word meaning 'an actor of second-class parts'.
Related